Skip to content
10-Q

Quarterly Report

Terns Pharmaceuticals, Inc.

0000950170-25-067003

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 87.34M sh
Shares Diluted Q1 2025 · Mar 31, 2025 91.47M sh
Shares Diluted Q1 2025 · Mar 31, 2024 74.4M sh
Capex Q1 2025 · Mar 31, 2025 $0
Capex Q1 2025 · Mar 31, 2024 $29K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$24.44M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$22.8M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $139.02M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $161.44M
Stockholders Equity Q1 2025 · Mar 31, 2025 $326.04M
Stockholders Equity Q1 2025 · Dec 31, 2024 $345.87M
Stockholders Equity Q1 2025 · Mar 31, 2024 $236.72M
Stockholders Equity Q1 2025 · Dec 31, 2023 $255.37M
Current Liabilities Q1 2025 · Mar 31, 2025 $10.94M
Current Liabilities Q1 2025 · Dec 31, 2024 $15.65M
Total Liabilities Q1 2025 · Mar 31, 2025 $13.27M
Total Liabilities Q1 2025 · Dec 31, 2024 $18.06M
Current Assets Q1 2025 · Mar 31, 2025 $337.75M
Current Assets Q1 2025 · Dec 31, 2024 $362.11M
Total Assets Q1 2025 · Mar 31, 2025 $339.32M
Total Assets Q1 2025 · Dec 31, 2024 $363.93M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.26
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.30
Eps Basic Q1 2025 · Mar 31, 2025 −$0.26
Eps Basic Q1 2025 · Mar 31, 2024 −$0.30
Sga Expense Q1 2025 · Mar 31, 2025 $8.71M
Sga Expense Q1 2025 · Mar 31, 2024 $6.86M
Net Income Q1 2025 · Mar 31, 2025 −$23.91M
Net Income Q1 2025 · Mar 31, 2024 −$22.37M
Operating Income Q1 2025 · Mar 31, 2025 −$27.43M
Operating Income Q1 2025 · Mar 31, 2024 −$25.45M